Standard 6: Age groups for pediatric trials

Pediatrics

Volumn 129, Issue SUPPL. 3, 2012, Pages

  Williams, Katrina ^a   Thomson, Denise ^b   Seto, Iva ^b   Contopoulos Ioannidis, Despina G ^c,d   Ioannidis, John P A ^c   Curtis, Sarah ^b   Constantin, Evelyn ^e   Batmanabane, Gitanjali ^f   Hartling, Lisa ^b   Klassen, Terry ^g,h   Offringa, Martin ⁱ  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b UNIVERSITY OF ALBERTA   (Canada)

^c STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PALO ALTO MEDICAL FOUNDATION RESEARCH INSTITUTE   (United States)

^e MONTREAL CHILDREN S HOSPITAL   (Canada)

^f WORLD HEALTH ORGANIZATION   (Switzerland)

^g MANITOBA INSTITUTE OF CHILD HEALTH   (Canada)

^h UNIVERSITY OF MANITOBA   (Canada)

ⁱ NONE

Author keywords

Age group; Age related analysis; Age related stratification; Pediatric; Randomized trials; StaR child health

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; DIAZEPAM; LORAZEPAM; PHENOBARBITAL; SEROTONIN UPTAKE INHIBITOR; SUCROSE;

AGE DISTRIBUTION; ASTHMA; BACTERIAL MENINGITIS; BRAIN MALARIA; CHILD; CHILD DEVELOPMENT; CHILD HEALTH CARE; CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); COGNITIVE THERAPY; CONFERENCE PAPER; CONVULSION; DEPRESSION; DISEASE EXACERBATION; DRUG APPROVAL; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ECZEMA; EFFECT SIZE; EPILEPTIC STATE; EVIDENCE BASED MEDICINE; HEALTH CARE DELIVERY; HEALTH CARE UTILIZATION; HUMAN; MORTALITY; OUTCOME ASSESSMENT; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL RATE; TREATMENT INDICATION; TREATMENT PLANNING; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VALIDATION PROCESS;

AGE FACTORS; CHILD; CLINICAL TRIALS AS TOPIC; HUMANS; PATIENT SELECTION; PEDIATRICS; PRACTICE GUIDELINES AS TOPIC;

EID: 84861918224     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2012-0055I     Document Type: Conference Paper

References (41)

1. Contopoulos-Ioannidis DG, Baltogianni MS, Ioannidis JP. Comparative effectiveness of medical interventions in adults versus children. J Pediatr. 2010;157(2):322-330, e17
2. Dunne J, Rodriguez WJ, Murphy MD, et al. Extrapolation of adult data and other data in pediatric drug-development programs. Pediatrics. 2011;128(5). Available at: www.pediatrics.org/cgi/content/full/128/5/e1242
3. Johann-Liang R, Wyeth J, Chen M, Cope JU. Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003-2007. Pharmacoepidemiol Drug Saf. 2009;18(1):24-27
4. 2-adrenergic receptor agonists. Pediatrics. 2011;128(5). Available at: www.pediatrics.org/cgi/content/full/128/ 5/e1147
5. Benjamin DK Jr, Smith PB, Sun MJ, et al. Safety and transparency of pediatric drug trials. Arch Pediatr Adolesc Med. 2009;163 (12):1080-1086
6. Smith PB, Benjamin DK Jr, Murphy MD, et al. Safety monitoring of drugs receiving pediatric marketing exclusivity. Pediatrics. 2008;122(3). Available at: www.pediatrics. org/cgi/content/full/122/3/e628
7. Forrest CB, Simpson L, Clancy C. Child health services research. Challenges and opportunities. JAMA. 1997;277(22):1787-1793 (Pubitemid 27247165)
8. Schor EL. Use of health care services by children and diagnoses received during presumably stressful life transitions. Pediatrics. 1986;77(6):834-841 (Pubitemid 16066298)
9. Chedoe I, Molendijk HA, Dittrich STAM, et al. Incidence and nature of medication errors in neonatal intensive care with strategies to improve safety: a review of the current literature. Drug Saf. 2007;30(6):503-513 (Pubitemid 46873075)
10. Stevens B, Yamada J, Ohlsson A. Sucrose for analgesia in newborn infants undergoing painful procedures. Cochrane Database Syst Rev. 2010;(1):CD001069
11. Harrison D, Bueno M, Yamada J, Adams-Webber T, Stevens B. Analgesic effects of sweet-tasting solutions for infants: current state of equipoise. Pediatrics. 2010;126(5): 894-902
12. Frey U, von Mutius E. The challenge of managing wheezing in infants. N Engl J Med. 2009;360(20):2130-2133
13. Waldman RJ, Hall WN, McGee H, Van Amburg G. Aspirin as a risk factor in Reye's syndrome. JAMA. 1982;247(22):3089-3094 (Pubitemid 12114461)
14. Sulieman MA. An overview of tooth-bleaching techniques: chemistry, safety and efficacy. Periodontol 2000. 2008;48: 148-169
15. Johnston CC, Fernandes AM, Campbell-Yeo M. Pain in neonates is different. Pain. 2011; 152(suppl 3):S65-S73
16. Khan KA, Weisman SJ. Nonpharmacologic pain management strategies in the pediatric emergency department. Clin Pediatr Emerg Med. 2007;8:240-247 (Pubitemid 350163034)
17. Eldridge C, Kennedy R. Nonpharmacologic techniques for distress reduction during emergency medical care: a review. Clin Pediatr Emerg Med. 2010;11(4):244-250
18. Savoye M, Nowicka P, Shaw M, et al. Longterm results of an obesity program in an ethnically diverse pediatric population. Pediatrics. 2011;127(3):402-410
19. Collins CE, Okely AD, Morgan PJ, et al. Parent diet modification, child activity, or both in obese children: an RCT. Pediatrics. 2011;127(4):619-627
20. Magarey AM, Perry RA, Baur LA, et al. A parent-led family-focused treatment program for overweight children aged 5 to 9 years: the PEACH RCT. Pediatrics. 2011;127 (2):214-222
21. Williams KW, Wray JJ, Wheeler DM. Intravenous secretin for autism spectrum disorder. Cochrane Database Syst Rev. 2005;(3):CD003495
22. Boyle RJ, Bath-Hextall FJ, Leonardi-Bee J, Murrell DF, Tang ML. Probiotics for treating eczema. Cochrane Database Syst Rev. 2008; (4):CD006135
23. Ersser SJ, Latter S, Sibley A, Satherley PA, Welbourne S. Psychological and educational interventions for atopic eczema in children. Cochrane Database Syst Rev. 2007;(3):CD004054
24. Hetrick S, Merry S, McKenzie J, Sindahl P, Proctor M. Selective serotonin reuptake inhibitors (SSRIs) for depressive disorders in children and adolescents. Cochrane Database Syst Rev. 2007;(3):CD004851
25. Siontis GC, Tzoulaki I, Ioannidis JP. Predicting death: an empirical evaluation of predictive tools for mortality. Arch Intern Med. 2011;171(19):1721-1726
26. Kent DM, Rothwell PM, Ioannidis JP, Altman DG, Hayward RA. Assessing and reporting heterogeneity in treatment effects in clinical trials: a proposal. Trials. 2010;11:85
27. Oxman AD, Guyatt GH. A consumer's guide to subgroup analyses. Ann Intern Med. 1992;116(1):78-84
28. Rothwell PM. Treating individuals 2. Subgroup analysis in randomised controlled trials: importance, indications, and interpretation. Lancet. 2005;365(9454):176-186 (Pubitemid 40091809)
29. Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine-reporting of subgroup analyses in clinical trials. N Engl J Med. 2007;357(21):2189-2194
30. Klassen TP, Hartling L, Craig JC, Offringa M. Children are not just small adults: the urgent need for high-quality trial evidence in children. PLoS Med. 2008;5(8):e172
31. Thomson D, Hartling L, Cohen E, Vandermeer B, Tjosvold L, Klassen TP. Controlled trials in children: quantity, methodological quality and descriptive characteristics of pediatric controlled trials published 1948-2006. PLoS ONE. 2010;5(9). pii: e13106
32. Thompson SG, Higgins JP. Treating individuals 4: can meta-analysis help target interventions at individuals most likely to benefit? Lancet. 2005;365(9456):341-346 (Pubitemid 40139113)
33. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database-update and key issues. N Engl J Med. 2011; 364(9):852-860
34. NICHD. Pediatric Terminology. Available at: http://bioportal bioontology org/ontologies/ 45989?p=terms. Accessed June 7, 2011
35. US Department of Health and Human Services. Development & Approval Process (Drugs). Forms & Submission Requirements. Pediatrics Exclusivity Study Age Group. Available at: www. fda.gov/Drugs/DevelopmentApprovalProcess/ FormsSubmissionRequirements/Electronic Submissions/DataStandardsManualmono graphs/ucm071754.htm. Accessed March 7 2012
36. US Department of Health and Human Services. Development & Approval Process (Drugs). Developmental Resources. Qualifying for Pediatric Exclusivity Under Section 505A of the Federal Food, Drug and Cosmetic Act: Frequently Asked Questions on Pediatric Exclusivity (505A), The Pediatric "Rule," and their Interaction. Answer to Question 24. Available at: www.fda.gov/Drugs/ DevelopmentApprovalProcess/Development Resources/ucm077915.htm. Accessed March 7, 2012
37. Brown B. Delphi Process: A Methodology Used for the Elicitation of Opinions of Experts. Santa Monica, CA: Rand Corporation; 1968
38. Dalkey N. The Delphi Method: An Experimental Study of Group Opinion. Santa Monica, CA: RAND Corporation; 1969
39. Byrne S, Wake M, Blumberg D, Dibley M. Identifying priority areas for longitudinal research in childhood obesity: Delphi technique survey. Int J Pediatr Obes. 2008;3 (2):120-122 (Pubitemid 351935297)
40. Herrmann KH, Kirchberger I, Stucki G, Cieza A. The comprehensive ICF core sets for spinal cord injury from the perspective of occupational therapists: a worldwide validation study using the Delphi technique. Spinal Cord. 2011;49(5):600-613
41. Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. PLoS ONE. 2011;6(6):e20476